ACW · ASX

Actinogen Medical Limited (ASX:ACW)

AU$0.025

 0.0 (0.0%)
ASX:Live
20/12/2024 04:10:10 PM
HALO Ords HALO Earnings Momentum GROWTH AUS Fakey Shakey - Long EMA 125 Breakdown +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ACW Overview

ACW Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Weak

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ACW

Website

Actinogen Medical Limited

Telephone

61.2.8964.7401

Address

Level 9 Suite 901 109 Pitt Street Sydney, New South Wales (NSW) 2000

Description

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company was founded by Geoff E. D. Brooke & David Keast on March 23, 1999 and is headquartered in Sydney, Australia.

ACW Price Chart

Key Stats

Market Cap

AU$81.45M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.1

Trade Value (12mth)

AU$72,851.00

1 week

-10.71%

1 month

0%

YTD

20.7%

1 year

10.2%

All time high

0.84

Key Fundamentals

EPS 3 yr Growth

130.80%

EBITDA Margin

N/A

Operating Cashflow

-$17m

Free Cash Flow Return

-101.60%

ROIC

-78.20%

Interest Coverage

-937.40

Quick Ratio

13.90

Other Data

Shares on Issue (Fully Dilluted)

2683m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ACW Announcements

Latest Announcements

Date Announcements

19 December 24

Change in substantial holding

×

Change in substantial holding

16 December 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

13 December 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

13 December 24

Listed Options Top 20 & Distribution Schedule

×

Listed Options Top 20 & Distribution Schedule

13 December 24

ACW to list $0.05 options exp 31 May 2027 - ASX code ACWOD

×

ACW to list $0.05 options exp 31 May 2027 - ASX code ACWOD

09 December 24

ACW randomizes first US participant in Alzheimers trial

×

ACW randomizes first US participant in Alzheimers trial

05 December 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

03 December 24

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

28 November 24

Notification of cessation of securities - ACW

×

Notification of cessation of securities - ACW

14 November 24

Actinogen 2024 AGM, Chairs address and CEOs presentation

×

Actinogen 2024 AGM, Chairs address and CEOs presentation

14 November 24

Results of Annual General Meeting

×

Results of Annual General Meeting

12 November 24

Actinogen receives $9.0 million R&D tax incentive rebate

×

Actinogen receives $9.0 million R&D tax incentive rebate

06 November 24

Notification of buy-back - ACW

×

Notification of buy-back - ACW

04 November 24

Results of General Meeting

×

Results of General Meeting

04 November 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

04 November 24

Application for quotation of securities - ACW

×

Application for quotation of securities - ACW

04 November 24

Cleansing Notice

×

Cleansing Notice

04 November 24

Appendix 3Ys x 4

×

Appendix 3Ys x 4

31 October 24

ACW CMO presents academic poster at CTAD 2024 conference

×

ACW CMO presents academic poster at CTAD 2024 conference

30 October 24

ACW September 2024 quarterly activity report & Appendix 4C

×

ACW September 2024 quarterly activity report & Appendix 4C

29 October 24

Actinogen appoints Andrew Udell as Chief Commercial Officer

×

Actinogen appoints Andrew Udell as Chief Commercial Officer

29 October 24

Issue of SPP shares & attaching listed options following GM

×

Issue of SPP shares & attaching listed options following GM

11 October 24

ACW Dementia Trials Australia presentation

×

ACW Dementia Trials Australia presentation

11 October 24

Letter to Shareholders, Notice of AGM & Proxy Form

×

Letter to Shareholders, Notice of AGM & Proxy Form

11 October 24

Annual Report to Shareholders

×

Annual Report to Shareholders

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ACW Shortsell

Frequently Asked Questions

The current share price of Actinogen Medical Limited (ACW:ASX) is AU$0.025.
The 52-week high share price for Actinogen Medical Limited (ACW:ASX) is AU$0.10.
The 52-week low share price for Actinogen Medical Limited (ACW:ASX)? is AU$0.02.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) does not pay a dividend.
Actinogen Medical Limited (ACW:ASX) has a franking level of 0.0%.
Actinogen Medical Limited (ACW:ASX) is classified in the Healthcare.
The current P/E ratio for Actinogen Medical Limited (ACW:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.